NBIX Neurocrine Biosciences, Inc. - Common Stock
$154,36
Preço · Ago 18, 2026
Fundamentais a partir de Jul 31, 2026
Intervalo 52 Semanas
$123–$186
50% of range
Classificação do Analista
BUY
36 analysts
Preço-Alvo
$212
+37% upside
P/E (TTM)
33.1
ROE
16.1%
Margem de Lucro Líquido
16.7%
Sobre Neurocrine Biosciences, Inc. - Common Stock Visão geral da empresa da Wikipedia
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
Ler mais
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.
History
Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.
In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.
In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.
In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.
In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.
Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.
On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.
In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.
In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.
In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.
In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.
In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.
Product pipeline
Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids
Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease
NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist
NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
NBIX Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$154.36
Capitalização de Mercado
$15.45B
P/E (TTM)
33.1
EPS (TTM)
$4.67
Receita (TTM)
$2.86B
Rendimento div.
—
ROE
16.1%
Dívida/Capital
—
Intervalo 52 Semanas
$123 – $186
NBIX Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$2.86B
2016-12-31
→
2025-12-31
EPS
$4.67
2016-12-31
→
2025-12-31
Fluxo de caixa livre
$749M
2016-12-31
→
2025-12-31
Margens
16.7%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
NBIX
Mediana de Pares
P/E (TTM)
33.1
16.9
P/S (TTM)
5.4
9.6
P/B
4.7
7.7
Price / FCF (Preço / FCF)
20.6
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
NBIX
Mediana de Pares
Operating Margin (Margem Operacional)
21.6%
—
Net Profit Margin (Margem de Lucro Líquido)
16.7%
-36.9%
ROA
11.5%
-21.8%
ROE
16.1%
-47.3%
ROIC
12.9%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
NBIX
Mediana de Pares
Current Ratio (Índice de liquidez corrente)
3.4
3.5
Quick Ratio (Índice de Liquidez Seca)
1.9
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
NBIX
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
21.4%
—
Revenue CAGR 3Y (CAGR Receita 3A)
24.3%
—
Revenue CAGR 5Y (CAGR Receita 5A)
22.3%
—
EPS YoY
41.9%
—
Net Income YoY (Lucro Líquido Ano a Ano)
40.2%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
NBIX
Mediana de Pares
NBIX Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
36 analistas
- Compra forte 14 38,9%
- Compra 17 47,2%
- Manter 5 13,9%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
27 analistas · 2026-08-15
Mediana
$215.00
← Abaixo de todos os alvos
$154.36
Mín
$165.00
Máx
$249.00
Alvo mediano
$215.00
+39,3%
Alvo médio
$211.57
+37,1%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.24%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $1.39 | $1.37 | 0.02% |
| 31 de Março de 2026 | $1.91 | $1.20 | 0.71% |
| 31 de Dezembro de 2025 | $1.91 | $1.20 | 0.71% |
| 30 de Setembro de 2025 | $2.04 | $1.62 | 0.42% |
| 30 de Junho de 2025 | $1.06 | $0.99 | 0.07% |
| 31 de Março de 2025 | $0.08 | $0.56 | -0.48% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Cost of Revenue | $52M | $34M | $40M | $23M | $14M | $10M | · | $5M | $1M | $0 | $0 | · | |
| R&D Expense | · | · | · | · | · | · | · | $161M | $122M | $94M | $81M | $46M | |
| SG&A Expense | $1.16B | $1.01B | $888M | $753M | $583M | $433M | $354M | $249M | $170M | $68M | $32M | $18M | |
| Operating Expenses | $2.24B | $1.78B | $1.64B | $1.24B | $1.03B | $883M | $716M | $414M | $293M | $162M | $114M | $64M | |
| Operating Income | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | $-94M | $-64M | |
| Interest Expense | · | · | $5M | $7M | $26M | $33M | $32M | $30M | $20M | $0 | $0 | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $3M | $2M | $629.0K | |
| Other Non-op | $86M | $-84M | $81M | $-35M | $-1M | $-56M | $-26M | $-15M | $-11M | $6M | $20.0K | $18.0K | |
| Pretax Income | $705M | $486M | $332M | $214M | $101M | $107M | $46M | $22M | $-143M | $-141M | · | · | |
| Income Tax | $227M | $145M | $82M | $59M | $12M | $-301M | $10M | $700.0K | $0 | $0 | $0 | $0 | |
| Net Income | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| EPS (Basic) | $4.81 | $3.40 | $2.56 | $1.61 | $0.95 | $4.38 | $0.40 | $0.23 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| EPS (Diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| Shares (Basic) | 99,500,000 | 100,400,000 | 97,700,000 | 95,800,000 | 94,600,000 | 93,100,000 | 91,600,000 | 90,200,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| Shares (Diluted) | 102,500,000 | 103,700,000 | 101,000,000 | 98,900,000 | 97,900,000 | 97,800,000 | 95,700,000 | 95,400,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| EBITDA | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | · | $-64M |
Balanço Patrimonial 28
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $713M | $233M | $251M | $263M | $341M | $187M | $112M | $142M | $255M | $83M | $74M | $31M | |
| Short-term Investments | · | · | · | · | $370M | $614M | $558M | $509M | $261M | $224M | $305M | $163M | |
| Receivables | $687M | $479M | $439M | $350M | $186M | $157M | $127M | $57M | $31M | $0 | · | · | |
| Inventory | $69M | $57M | $38M | $35M | $30M | $28M | $17M | $11M | $1M | $0 | · | · | |
| Prepaid Expense | $171M | $48M | · | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $116M | $64M | $98M | $79M | $46M | $30M | $17M | $19M | $7M | $3M | $5M | $4M | |
| Current Assets | $2.52B | $1.72B | $1.61B | $1.45B | $973M | $1.02B | $831M | $738M | $555M | $310M | $384M | $198M | |
| PP&E (Net) | $90M | $83M | $71M | $59M | $59M | $45M | $42M | $34M | $11M | $6M | $3M | $3M | |
| PP&E (Gross) | $208M | $189M | $154M | $125M | $110M | $86M | $76M | $62M | $38M | $32M | $30M | $31M | |
| Accum. Depreciation | $118M | $106M | $83M | $66M | $52M | $42M | $34M | $28M | $28M | $26M | $27M | $29M | |
| Goodwill | $6M | $6M | $6M | $5M | $0 | · | · | · | · | · | · | · | |
| Intangibles | $5M | $36M | $36M | $37M | $0 | · | · | · | · | · | · | · | |
| Other Non-current Assets | $49M | $52M | $50M | $25M | $4M | $6M | $0 | · | · | · | · | · | |
| Total Assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Accounts Payable | $674M | $462M | $449M | $348M | $226M | $169M | $141M | $86M | $6M | $5M | $3M | $246.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | $21M | $19M | $12M | |
| Current Liabilities | $743M | $508M | $655M | $538M | $246M | $186M | $565M | $88M | $54M | $30M | $26M | $16M | |
| Capital Leases | $415M | $455M | $258M | $94M | $105M | $94M | $87M | $0 | · | · | · | · | |
| Deferred Tax | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $220M | $166M | $106M | $30M | $12M | $10M | $17M | $36M | $0 | $113.0K | $221.0K | $260.0K | |
| Total Liabilities | $1.38B | $1.13B | $1.02B | $661M | $698M | $608M | $669M | $512M | $445M | $50M | $50M | $34M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $91.0K | $89.0K | $87.0K | $86.0K | $76.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | $1.04B | |
| Retained Earnings | $448M | $29M | $-157M | $-407M | $-636M | $-725M | $-1.13B | $-1.18B | $-1.20B | $-1.06B | $-915M | $-826M | |
| AOCI | $13M | $6M | $7M | $-8M | $-2M | $2M | $1M | $-2M | $-2M | $-318.0K | $-977.0K | $-277.0K | |
| Stockholders' Equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B | $637M | $481M | $372M | $315M | $424M | $209M | |
| Liabilities + Equity | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Shares Outstanding | 100,100,000 | 99,400,000 | 98,700,000 | 96,500,000 | 94,900,000 | 93,500,000 | 92,300,000 | 90,797,000 | 88,793,903 | 86,883,300 | 86,262,594 | 76,465,942 |
Fluxo de Caixa 15
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $4M | $2M | $1M | $1M | $827.0K | |
| Stock-based Comp | $218M | $196M | $194M | $173M | $134M | $100M | $75M | $58M | $43M | $28M | $28M | $10M | |
| Deferred Tax | $164M | $-123M | $-61M | $22M | $6M | $-311M | $0 | $0 | · | · | · | · | |
| Amort. of Intangibles | $4M | $4M | $4M | $500.0K | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $783M | $595M | $390M | $339M | $256M | $228M | $147M | $101M | $-94M | $-106M | $-38M | $-47M | |
| CapEx | $34M | $38M | $28M | $16M | $23M | $11M | $15M | $25M | $7M | $4M | $2M | $2M | |
| Investing Cash Flow | $-264M | $-127M | $-467M | $-177M | $-130M | $4M | $-211M | $-243M | $-251M | $113M | · | · | |
| Stock Issued | $129M | $122M | $65M | $45M | $28M | $29M | $32M | $30M | $14M | $2M | $277M | $139M | |
| Stock Repurchased | $168M | $300M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-38M | $-178M | $65M | $45M | $28M | $29M | $27M | $30M | $14M | $2M | · | $139M | |
| Financing Cash Flow | $-38M | $-487M | $65M | $-234M | $27M | $-158M | $32M | $30M | $517M | $2M | · | · | |
| Net Change in Cash | $480M | $-18M | $-12M | $-73M | $154M | $75M | $-32M | $-112M | $171M | $9M | $43M | $-14M | |
| Taxes Paid | $81M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $749M | $557M | $362M | $323M | $233M | $218M | $137M | $77M | $-101M | $-110M | · | $-49M | |
| Levered FCF | · | · | $358M | $318M | $210M | $92M | $112M | $47M | · | · | · | · |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| Net Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% | · | · | |
| Pretax Margin | 24.7% | 20.6% | 17.6% | 14.4% | 8.9% | 10.2% | 5.9% | 4.8% | · | · | · | · | |
| EBITDA Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| ROA | 11.5% | 9.8% | 8.9% | 7.0% | 4.7% | 26.8% | 3.2% | 2.3% | -24.1% | -33.6% | · | -30.4% | |
| ROE | 16.1% | 12.9% | 11.8% | 9.5% | 6.6% | 42.2% | 6.1% | 4.5% | -41.5% | -38.2% | · | -36.8% | |
| ROIC | 12.9% | 15.5% | 8.5% | 10.5% | 6.6% | 55.2% | 9.0% | 7.4% | · | · | · | · |
Liquidez e Solvência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 | 5.4 | 1.5 | 8.4 | 10.2 | 10.2 | · | 12.7 | |
| Quick Ratio | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 | 5.1 | 1.4 | 2.2 | 10.1 | 10.1 | · | 12.4 | |
| Interest Coverage | · | · | 54.5 | 35.1 | 4.0 | 5.0 | 2.3 | 1.2 | -6.7 | · | · | · |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.6 | 0.7 | 0.7 | 0.5 | 0.3 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.8 | 0.7 | 1.1 | 0.7 | · | · | · | 0.8 | · | · | · | · | |
| Receivables Turnover | 4.9 | 5.1 | 4.8 | 5.6 | 6.6 | 7.4 | 8.6 | 10.3 | 10.4 | · | · | · |
Taxas de Crescimento 9
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 21.4% | 24.8% | 26.8% | 31.3% | 8.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 24.3% | 27.6% | 21.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 22.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 41.9% | 33.2% | 58.3% | 69.6% | -77.9% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 44.1% | 52.9% | -16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 2.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 40.2% | 36.7% | 61.6% | 72.4% | -78.0% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 45.8% | 56.2% | -15.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 3.3% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Net Income TTM | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| Market Cap | $14.20B | $13.57B | $13.00B | $11.53B | $8.08B | $8.96B | $9.92B | $6.48B | $6.89B | $3.36B | · | $1.71B | |
| P/E | 30.4 | 41.5 | 53.3 | 76.6 | 92.6 | 23.0 | 275.6 | 324.6 | -47.9 | -23.7 | -53.9 | -27.6 | |
| P/S | 5.0 | 5.8 | 6.9 | 7.7 | 7.1 | 8.6 | 12.6 | 14.4 | 42.6 | 224.2 | · | · | |
| P/B | 4.4 | 5.2 | 5.8 | 6.7 | 5.9 | 8.0 | 15.6 | 13.5 | 18.5 | 10.7 | · | 8.2 | |
| P / Tangible Book | 4.4 | 5.3 | 5.9 | 6.9 | 5.9 | 8.0 | · | · | · | · | · | · | |
| P / Cash Flow | 18.1 | 22.8 | 33.4 | 34.0 | 31.5 | 39.2 | 65.2 | 64.0 | -73.0 | -31.7 | · | -36.2 | |
| P / FCF | 19.0 | 24.4 | 36.0 | 35.7 | 34.7 | 41.2 | 72.2 | 84.7 | -68.0 | -30.5 | · | -35.0 | |
| Earnings Yield | 3.3% | 2.4% | 1.9% | 1.3% | 1.1% | 4.3% | 0.36% | 0.31% | -2.1% | -4.2% | -1.9% | -3.6% |
Demonstração de Resultados 15
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $959M | $814M | $806M | $795M | $688M | $573M | $628M | $622M | $590M | $515M | $515M | $499M | $453M | $420M | $412M | $388M | |
| Cost of Revenue | · | $14M | $18M | $14M | $11M | $9M | $9M | $8M | $9M | $8M | $8M | $11M | $12M | $8M | $8M | $6M | |
| SG&A Expense | $440M | $318M | $302M | $292M | $286M | $276M | $288M | $234M | $242M | $243M | $219M | $204M | $222M | $243M | $183M | $186M | |
| Operating Expenses | $808M | $621M | $595M | $556M | $542M | $549M | $486M | $438M | $445M | $416M | $365M | $358M | $379M | $535M | $309M | $300M | |
| Operating Income | $152M | $193M | $211M | $239M | $146M | $24M | $142M | $184M | $145M | $99M | $150M | $141M | $74M | $-114M | $103M | $88M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-op | $11M | $53M | $28M | $53M | $14M | $-9M | $21M | $6M | $-47M | $-65M | $48M | $-26M | $48M | $11M | $14M | $10M | |
| Pretax Income | $162M | $247M | $239M | $292M | $160M | $15M | $163M | $190M | $99M | $34M | $198M | $116M | $122M | $-103M | $118M | $98M | |
| Income Tax | $18M | $49M | $86M | $82M | $52M | $7M | $60M | $60M | $34M | $-9M | $50M | $32M | $26M | $-27M | $29M | $29M | |
| Net Income | $144M | $198M | $154M | $210M | $108M | $8M | $103M | $130M | $65M | $43M | $148M | $83M | $96M | $-77M | $89M | $68M | |
| EPS (Basic) | $1.43 | $1.97 | $1.53 | $2.11 | $1.09 | $0.08 | $1.05 | $1.28 | $0.64 | $0.43 | $1.52 | $0.85 | $0.98 | $-0.79 | $0.92 | $0.72 | |
| EPS (Diluted) | $1.39 | $1.91 | $1.49 | $2.04 | $1.06 | $0.08 | $1.00 | $1.24 | $0.63 | $0.42 | $1.49 | $0.82 | $0.95 | $-0.79 | $0.91 | $0.69 | |
| Shares (Basic) | 101,000,000 | 100,500,000 | -198,600,000 | 99,400,000 | 99,000,000 | 99,700,000 | -201,300,000 | 101,100,000 | 100,800,000 | 99,800,000 | -194,900,000 | 97,900,000 | 97,600,000 | 97,100,000 | -190,900,000 | 95,800,000 | |
| Shares (Diluted) | 104,200,000 | 103,400,000 | -203,500,000 | 102,500,000 | 101,000,000 | 102,500,000 | -208,100,000 | 104,300,000 | 103,900,000 | 103,600,000 | -197,400,000 | 101,100,000 | 100,200,000 | 97,100,000 | -193,300,000 | 99,000,000 | |
| EBITDA | $152M | $193M | · | $239M | $146M | $24M | · | $184M | $145M | $99M | · | $141M | $74M | $-114M | · | $88M |
Balanço Patrimonial 25
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $332M | $266M | $713M | $340M | $264M | $194M | $233M | $349M | $140M | $396M | · | $294M | $160M | $104M | · | $212M | |
| Receivables | $887M | $768M | $687M | $728M | $596M | $516M | $479M | $481M | $468M | $451M | · | $418M | $388M | $392M | · | $301M | |
| Inventory | $104M | $64M | $69M | $69M | $57M | $59M | $57M | $46M | $42M | $37M | · | $29M | $32M | $33M | · | $37M | |
| Prepaid Expense | $217M | $225M | $171M | $178M | · | · | $48M | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $39M | $62M | $116M | $68M | $121M | $119M | $64M | $122M | $120M | $100M | · | $108M | $101M | $113M | · | $68M | |
| Current Assets | $1.64B | $2.44B | $2.52B | $2.16B | $1.75B | $1.64B | $1.72B | $1.88B | $1.67B | $1.80B | · | $1.65B | $1.50B | $1.43B | · | $1.21B | |
| PP&E (Net) | $90M | $91M | $90M | $97M | $92M | $87M | $83M | $80M | $80M | $75M | · | $69M | $66M | $63M | · | $61M | |
| PP&E (Gross) | · | · | $208M | · | · | · | $189M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $118M | · | · | · | $106M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $501M | · | · | · | · | · | · | $6M | $6M | $6M | · | $6M | $6M | $6M | $5M | · | |
| Intangibles | $2.23B | · | · | $36M | $37M | $36M | · | $34M | $34M | $34M | · | $35M | $37M | $37M | · | · | |
| Other Non-current Assets | $59M | $74M | $60M | $20M | $22M | $15M | $52M | $62M | $58M | $51M | · | $43M | $36M | $25M | · | $10M | |
| Total Assets | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Accounts Payable | $808M | $773M | $674M | $584M | $490M | $475M | $462M | $393M | $358M | $417M | · | $503M | $392M | $356M | · | $298M | |
| Current Liabilities | $874M | $832M | $743M | $638M | $546M | $523M | $508M | $430M | $398M | $713M | · | $692M | $582M | $374M | · | $485M | |
| Capital Leases | $402M | $406M | $415M | $428M | $439M | $448M | $455M | $251M | $256M | $253M | · | $86M | $89M | $90M | · | $97M | |
| Deferred Tax | $92M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $298M | $261M | $220M | $196M | $210M | $182M | $166M | $135M | $141M | $120M | · | $69M | $88M | $41M | · | $17M | |
| Total Liabilities | $1.67B | $1.50B | $1.38B | $1.26B | $1.20B | $1.15B | $1.13B | $816M | $796M | $1.09B | · | $846M | $760M | $675M | · | $599M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Retained Earnings | $724M | $590M | $448M | $294M | $84M | $-5M | $29M | $81M | $-49M | $-114M | · | $-305M | $-388M | $-483M | · | $-496M | |
| AOCI | $5M | $400.0K | $13M | $13M | $12M | $9M | $6M | $14M | $2M | $3M | · | $-2M | $-1M | $-3M | · | $-14M | |
| Stockholders' Equity | $3.69B | $3.41B | $3.25B | $3.00B | $2.69B | $2.54B | $2.59B | $2.72B | $2.51B | $2.39B | $2.23B | $2.00B | $1.85B | $1.68B | $1.71B | $1.54B | |
| Liabilities + Equity | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Shares Outstanding | 101,600,000 | 100,600,000 | 100,100,000 | 99,700,000 | 99,000,000 | 99,000,000 | 99,400,000 | 101,200,000 | 100,900,000 | 100,600,000 | · | 98,200,000 | 97,600,000 | 97,500,000 | · | 96,100,000 |
Fluxo de Caixa 12
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $65M | $57M | $59M | $54M | $53M | $53M | $66M | $42M | $43M | $44M | $38M | $48M | $68M | $40M | $44M | $43M | |
| Amort. of Intangibles | $16M | $100.0K | $1M | $1M | $1M | $1M | $900.0K | $900.0K | $900.0K | $900.0K | $800.0K | $900.0K | $900.0K | $900.0K | $500.0K | $0 | |
| Operating Cash Flow | $136M | $146M | $388M | $228M | $102M | $65M | $242M | $158M | $65M | $130M | $124M | $212M | $180M | $-125M | $143M | $99M | |
| CapEx | $8M | $9M | $-2M | $13M | $12M | $11M | $7M | $8M | $12M | $11M | $5M | $8M | $7M | $8M | $2M | $-2M | |
| Investing Cash Flow | $-135M | $-506M | $-53M | $-197M | $-29M | $14M | $-68M | $25M | $-28M | $-55M | $-202M | $-97M | $-126M | $-42M | $-116M | $-61M | |
| Stock Issued | $85M | $24M | $37M | $46M | $14M | $32M | $10M | $26M | $16M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Stock Repurchased | $12M | $54M | $0 | $0 | $18M | $150M | $300M | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | · | $-30M | · | · | · | $-118M | · | · | · | $70M | · | · | · | $8M | · | · | |
| Financing Cash Flow | $63M | $-86M | $37M | $46M | $-3M | $-118M | $-290M | $26M | $-293M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Net Change in Cash | $64M | $-446M | $373M | $76M | $70M | $-39M | $-116M | $209M | $-257M | $145M | $-43M | $134M | $57M | $-159M | $51M | $49M | |
| Free Cash Flow | · | $137M | · | · | · | $54M | · | · | · | $119M | · | · | · | $-134M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $118M | · | · | · | $-135M | · | · |
Lucratividade 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| Net Margin | 15.1% | 24.3% | · | 26.4% | 15.6% | 1.4% | · | 20.9% | 11.0% | 8.4% | · | 16.7% | 21.1% | -18.2% | · | 17.7% | |
| Pretax Margin | 16.9% | 30.3% | · | 36.7% | 23.2% | 2.6% | · | 30.6% | 16.7% | 6.7% | · | 23.2% | 26.9% | -24.6% | · | 25.2% | |
| EBITDA Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| ROA | 3.1% | 4.6% | · | 5.4% | 3.0% | 0.22% | · | 4.1% | 2.2% | 1.5% | · | 3.3% | 4.1% | -3.4% | · | 3.3% | |
| ROE | 4.5% | 6.7% | · | 7.3% | 4.1% | 0.32% | · | 5.5% | 3.0% | 2.1% | · | 4.7% | 5.8% | -5.0% | · | 4.7% | |
| ROIC | 3.6% | 4.5% | · | 5.7% | 3.6% | 0.50% | · | 4.6% | 3.8% | 5.2% | · | 5.1% | 3.1% | -5.0% | · | 4.0% |
Liquidez e Solvência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.9 | · | 3.4 | 3.2 | 3.1 | · | 4.4 | 4.2 | 2.5 | · | 2.4 | 2.6 | 3.8 | · | 2.5 | |
| Quick Ratio | 1.4 | 1.2 | · | 1.7 | 1.6 | 1.4 | · | 1.9 | 1.5 | 1.2 | · | 1.0 | 0.9 | 1.3 | · | 1.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 90.3 | · | 128.4 | 56.6 | -103.8 | · | 73.2 |
Eficiência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | · | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.2 | · | 1.4 | 1.4 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.7 |
Avaliação (TTM) 10
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.26B | $2.87B | · | $2.68B | $2.47B | $2.30B | · | $2.23B | $2.06B | $1.89B | · | $1.76B | $1.64B | $1.50B | · | $1.37B | |
| Net Income TTM | $659M | $523M | · | $455M | $310M | $246M | · | $321M | $287M | $145M | · | $170M | $70M | $-11M | · | $88M | |
| Market Cap | $17.12B | $13.25B | · | $14.00B | $12.44B | $10.95B | · | $11.66B | $13.89B | $13.87B | · | $11.05B | $9.20B | $9.87B | · | $10.21B | |
| P/E | 26.3 | 25.9 | · | 31.8 | 41.8 | 46.7 | · | 37.0 | 48.8 | 98.5 | · | 67.4 | 140.7 | -723.0 | · | 120.7 | |
| P/S | 5.3 | 4.6 | · | 5.2 | 5.0 | 4.8 | · | 5.2 | 6.8 | 7.4 | · | 6.3 | 5.6 | 6.6 | · | 7.4 | |
| P/B | 4.6 | 3.9 | · | 4.7 | 4.6 | 4.3 | · | 4.3 | 5.5 | 5.8 | · | 5.5 | 5.0 | 5.9 | · | 6.6 | |
| P / Tangible Book | 17.7 | 3.9 | · | 4.7 | 4.7 | 4.4 | · | 4.4 | 5.6 | 5.9 | · | 5.6 | 5.1 | 6.0 | · | 6.6 | |
| P / Cash Flow | · | 90.9 | · | · | · | 169.0 | · | · | · | 106.5 | · | · | · | -78.8 | · | · | |
| P / FCF | · | 96.9 | · | · | · | 202.4 | · | · | · | 116.5 | · | · | · | -73.8 | · | · | |
| Earnings Yield | 3.8% | 3.9% | · | 3.1% | 2.4% | 2.1% | · | 2.7% | 2.1% | 1.0% | · | 1.5% | 0.71% | -0.14% | · | 0.83% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Margem Operacional % | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% |
| Lucro líquido | $479M | $341M | $250M | $154M | $90M |
| EPS Diluído | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 |
| Índice de Liquidez Seca | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $749M | $557M | $362M | $323M | $233M |
Últimas notícias Notícias recentes mencionando esta empresa
- Opções de Dezembro de 2027 Agora Disponíveis para Neurocrine Biosciences (NBIX)
- Mercado de Ações de Hoje, 6 de Abril: Soleno Therapeutics Aumenta Após Acordo de Aquisição em Dinheiro Total de US$2,9 Bilhões
- Neurocrine Adquire Soleno por US$ 2,9 Bilhões em Dinheiro; Ações da Soleno Disparam no Pré-mercado
Sinais de trading Sinais recentes de compra/venda com preço de entrada e relação risco/recompensa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 827 declarantes · $10.1B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 153 (+61 vs trimestre anterior) | 62 (-37 vs trimestre anterior) | 300 (+11 vs trimestre anterior) | 223 (+8 vs trimestre anterior) | +9.4M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| Dodge & Cox | $941.218.594 | 5.584.707 | 9,32% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $838.307.078 | 4.974.083 | 8,30% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $766.048.708 | 4.545.339 | 7,59% | Ações |
| STATE STREET CORP | $739.126.759 | 4.385.598 | 7,32% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $393.680.402 | 2.335.897 | 3,90% | Ações |
| TWO SIGMA INVESTMENTS, LP | $349.922.479 | 2.076.260 | 3,47% | Ações |
| Vestal Point Capital, LP | $316.845.800 | 1.880.000 | 3,14% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $294.151.210 | 1.750.392 | 2,91% | Ações |
| RTW INVESTMENTS, LP | $213.689.740 | 1.267.925 | 2,12% | Ações |
| NORGES BANK | $164.132.866 | 973.880 | 1,63% | Ações |
| FIRST TRUST ADVISORS LP | $155.578.851 | 923.125 | 1,54% | Ações |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $122.375.286 | 726.112 | 1,21% | Ações |
| TWO SIGMA ADVISERS, LP | $119.504.823 | 842.592 | 1,18% | Ações |
| Swedbank AB | $109.730.107 | 651.082 | 1,09% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $109.170.737 | 647.763 | 1,08% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $109.070.816 | 647.171 | 1,08% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $104.238.729 | 618.499 | 1,03% | Ações |
| Caisse de depot et placement du Quebec | $91.002.327 | 539.961 | 0,90% | Ações |
| ARMISTICE CAPITAL, LLC | $90.307.457 | 535.838 | 0,89% | Ações |
| PRIMECAP MANAGEMENT CO/CA/ | $82.807.988 | 491.340 | 0,82% | Ações |
| AMERIPRISE FINANCIAL INC | $79.666.260 | 472.708 | 0,79% | Ações |
| Hood River Capital Management LLC | $79.082.184 | 469.233 | 0,78% | Ações |
| ROYAL BANK OF CANADA | $73.348.000 | 435.207 | 0,73% | Ações |
| Pictet Asset Management Holding SA | $72.751.030 | 430.635 | 0,72% | Ações |
| Gotham Asset Management, LLC | $62.622.213 | 371.568 | 0,62% | Ações |
| Fiera Capital Corp | $61.558.083 | 365.254 | 0,61% | Ações |
| BlackRock, Inc. | $61.129.161 | 362.709 | 0,61% | Ações |
| ALLIANCEBERNSTEIN L.P. | $60.767.710 | 461.270 | 0,60% | Ações |
| Vinva Investment Management Ltd | $58.838.530 | 346.109 | 0,58% | Ações |
| AustralianSuper Pty Ltd | $58.817.535 | 348.993 | 0,58% | Ações |
| GOLDMAN SACHS GROUP INC | $58.206.259 | 345.366 | 0,58% | Ações |
| BRAIDWELL LP | $56.656.579 | 336.171 | 0,56% | Ações |
| RHUMBLINE ADVISERS | $52.723.054 | 312.832 | 0,52% | Ações |
| Clearbridge Investments, LLC | $47.391.031 | 281.194 | 0,47% | Ações |
| SEIZERT CAPITAL PARTNERS, LLC | $46.740.991 | 277.337 | 0,46% | Ações |
| Swiss National Bank | $45.319.062 | 268.900 | 0,45% | Ações |
| BARCLAYS PLC | $44.228.304 | 262.428 | 0,44% | Ações |
| ENVESTNET ASSET MANAGEMENT INC | $44.187.600 | 262.192 | 0,44% | Ações |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $44.038.027 | 261.299 | 0,44% | Ações |
| Candriam S.C.A. | $43.932.854 | 260.926 | 0,44% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $43.921.064 | 260.605 | 0,43% | Ações |
| FMR LLC | $40.551.501 | 240.612 | 0,40% | Ações |
| PRINCIPAL FINANCIAL GROUP INC | $40.285.595 | 239.034 | 0,40% | Ações |
| California Public Employees Retirement System | $39.090.345 | 231.942 | 0,39% | Ações |
| RENAISSANCE GROUP LLC | $38.589.515 | 228.970 | 0,38% | Ações |
| Assenagon Asset Management S.A. | $37.516.902 | 222.606 | 0,37% | Ações |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $37.508.000 | 222.554 | 0,37% | Ações |
| Sumitomo Mitsui Trust Group, Inc. | $36.317.270 | 215.488 | 0,36% | Ações |
| Carmignac Gestion | $36.083.344 | 214.100 | 0,36% | Ações |
| PFM Health Sciences, LP | $35.966.549 | 213.407 | 0,36% | Ações |
| Bridgewater Associates, LP | $34.663.773 | 205.677 | 0,34% | Ações |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $34.304.966 | 203.548 | 0,34% | Ações |
| Nantahala Capital Management, LLC | $33.707.000 | 200.000 | 0,33% | Opção de compra |
| BANK OF AMERICA CORP /DE/ | $32.143.164 | 190.721 | 0,32% | Ações |
| MORGAN STANLEY | $32.058.612 | 190.219 | 0,32% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31.213.608 | 185.200 | 0,31% | Opção de venda |
| FULLER & THALER ASSET MANAGEMENT, INC. | $30.192.001 | 179.149 | 0,30% | Ações |
| PRUDENTIAL FINANCIAL INC | $29.909.064 | 177.465 | 0,30% | Ações |
| SEB Asset Management AB | $29.789.208 | 176.754 | 0,30% | Ações |
| Ensign Peak Advisors, Inc | $29.653.059 | 175.946 | 0,29% | Ações |
| IEQ CAPITAL, LLC | $29.628.432 | 175.800 | 0,29% | Ações |
| MACKENZIE FINANCIAL CORP | $29.609.071 | 175.685 | 0,29% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $29.573.511 | 175.474 | 0,29% | Ações |
| Korea Investment CORP | $29.154.701 | 172.989 | 0,29% | Ações |
| PKO BP BANKOWY Universal Pension Society JSC | $28.786.115 | 170.802 | 0,29% | Ações |
| Zurich Insurance Group Ltd/FI | $28.618.254 | 169.806 | 0,28% | Ações |
| Impax Asset Management Group plc | $26.965.600 | 160.000 | 0,27% | Ações |
| Nearwater Capital Markets, Ltd | $26.122.925 | 155.000 | 0,26% | Ações |
| Mariner, LLC | $25.627.342 | 152.055 | 0,25% | Ações |
| Integral Health Asset Management, LLC | $25.281.000 | 150.000 | 0,25% | Ações |
| Rock Springs Capital Management LP | $24.395.441 | 144.750 | 0,24% | Ações |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $23.738.829 | 140.854 | 0,24% | Ações |
| Fisher Asset Management, LLC | $22.769.751 | 135.104 | 0,23% | Ações |
| Aware Super Pty Ltd as trustee of Aware Super | $22.056.175 | 130.870 | 0,22% | Ações |
| RAYMOND JAMES FINANCIAL INC | $22.009.323 | 130.592 | 0,22% | Ações |
| Hudson Bay Capital Management LP | $21.909.550 | 130.000 | 0,22% | Ações |
| Life Cycle Investment Partners Ltd | $21.287.319 | 126.308 | 0,21% | Ações |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $20.937.370 | 147.623 | 0,21% | Ações |
| DNB Asset Management AS | $20.280.996 | 120.337 | 0,20% | Ações |
| JANE STREET GROUP, LLC | $20.072.518 | 119.100 | 0,20% | Opção de venda |
| Sarissa Capital Management LP | $19.639.889 | 116.533 | 0,19% | Ações |
| Andra AP-fonden | $19.522.682 | 148.191 | 0,19% | Ações |
| AMERICAN CENTURY COMPANIES INC | $19.061.140 | 113.099 | 0,19% | Ações |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $18.885.863 | 112.059 | 0,19% | Ações |
| Man Group plc | $18.859.404 | 111.902 | 0,19% | Ações |
| Mitsubishi UFJ Asset Management Co., Ltd. | $18.788.956 | 111.484 | 0,19% | Ações |
| UBS Group AG | $18.243.577 | 108.248 | 0,18% | Ações |
| Robeco Institutional Asset Management B.V. | $18.197.736 | 107.976 | 0,18% | Ações |
| LOOMIS SAYLES & CO L P | $18.108.412 | 107.446 | 0,18% | Ações |
| Retirement Systems of Alabama | $17.527.134 | 103.997 | 0,17% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $17.474.389 | 132.643 | 0,17% | Ações |
| ING GROEP NV | $17.224.277 | 102.200 | 0,17% | Ações |
| Legal & General Group Plc | $17.176.748 | 101.918 | 0,17% | Ações |
| RICE HALL JAMES & ASSOCIATES, LLC | $16.886.364 | 100.195 | 0,17% | Ações |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $16.827.572 | 99.912 | 0,17% | Ações |
| CWM, LLC | $16.696.728 | 126.740 | 0,17% | Ações |
| CAPITAL FUND MANAGEMENT S.A. | $16.536.148 | 98.117 | 0,16% | Ações |
| Clark Capital Management Group, Inc. | $15.629.612 | 92.738 | 0,15% | Ações |
| Distillate Capital Partners LLC | $15.604.993 | 92.592 | 0,15% | Ações |
| LAZARD ASSET MANAGEMENT LLC | $15.399.211 | 91.371 | 0,15% | Ações |
Executivos da empresa 42 insiders · 21 diretores · 15 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Kyle Gano | Chief Executive Officer | 13 de Fevereiro de 2025 M | 139.907 | 0 | 0 | $0 |
| Matt Abernethy | Chief Financial Officer | 13 de Fevereiro de 2025 M | 35.810 | 0 | 0 | $0 |
| Timothy Coughlin | Chief Financial Officer | 6 de Fevereiro de 2017 S | 137.961 | 0 | 0 | $0 |
| David-Alexandre C Gros | President & COO | 6 de Fevereiro de 2017 A | — | 0 | 0 | $0 |
| Ingrid Delaet | Chief Regulatory Officer | 10 de Julho de 2026 M | 16.225 | 0 | 5 | $-3.747.962 |
| Darin Lippoldt | Chief Legal Officer | 9 de Julho de 2026 M | 54.729 | 0 | 4 | $-3.497.443 |
| Sanjay Chandru Keswani | Chief Medical Officer | 2 de Junho de 2026 F | 1.479 | 0 | 0 | $0 |
| Julie Cooke | Chief Human Resources Officer | 2 de Junho de 2026 M | 22.374 | 0 | 1 | $-2.200.685 |
| David W. Boyer | Chief Corp. Affairs Officer | 13 de Fevereiro de 2025 M | 3.565 | 0 | 0 | $0 |
| Eiry Roberts | Chief Medical Officer | 13 de Fevereiro de 2025 M | 35.640 | 0 | 0 | $0 |
| Eric Benevich | Chief Commercial Officer | 13 de Fevereiro de 2025 M | 44.689 | 0 | 0 | $0 |
| Malcolm Lloyd-Smith | Chief Integration Officer | 8 de Fevereiro de 2023 S | 42.337 | 0 | 0 | $0 |
| Dimitri E. Grigoriadis | Chief Research Officer | 31 de Janeiro de 2022 A | 82.273 | 0 | 0 | $0 |
| Haig P. Bozigian | Chief Development Officer | 8 de Fevereiro de 2021 A | 157.651 | 0 | 0 | $0 |
| Christopher Flint Obrien | Former Chief Medical Officer | 5 de Fevereiro de 2018 A | 55.946 | 0 | 0 | $0 |
| VALEUR JENSEN MARGARET E | EVP and General Counsel | 31 de Agosto de 2011 A | 118.256 | 0 | 0 | $0 |
| Richard J Ranieri | Sr. VP, Human Resources | 27 de Fevereiro de 2008 A | 9.667 | 0 | 0 | $0 |
| Wendall Wierenga | EVP, Research & Development | 19 de Janeiro de 2006 A | 5.023 | 0 | 0 | $0 |
| Henry Pan | Executive VP and CMO | 3 de Junho de 2005 A | 11.216 | 0 | 0 | $0 |
| Robert J Little | SVP, Commercial Operations | 18 de Fevereiro de 2005 A | — | 0 | 0 | $0 |
| SAUNDERS JOHN | Vice President Research (Chem) | 18 de Dezembro de 2003 S | 7.966 | 0 | 0 | $0 |
| Leslie V Norwalk | Conselheiro | 29 de Julho de 2026 M | 2.430 | 0 | 2 | $-437.584 |
| SHERWIN STEPHEN A | Conselheiro | 5 de Junho de 2026 M | 15.860 | 0 | 5 | $-4.132.990 |
| William H Rastetter | Conselheiro | 27 de Maio de 2026 A | 43.678 | 0 | 1 | $-2.732.760 |
| Kevin Charles Gorman | Conselheiro | 27 de Maio de 2026 A | 511.293 | 0 | 1 | $-37.824.431 |
| Christine A Poon | Conselheiro | 27 de Maio de 2026 A | 4.753 | 0 | 0 | $0 |
| POPS RICHARD F | Conselheiro | 27 de Maio de 2026 A | 37.798 | 0 | 1 | $-2.364.750 |
| LYONS GARY A | Conselheiro | 27 de Maio de 2026 A | 122.141 | 0 | 1 | $-2.289.150 |
| MORROW GEORGE J | Conselheiro | 27 de Maio de 2026 A | 10.386 | 0 | 1 | $-2.150.550 |
| Johanna Mercier | Conselheiro | 22 de Maio de 2025 M | 3.535 | 0 | 0 | $0 |
| Alfred Sandrock | Conselheiro | 22 de Maio de 2019 A | — | 0 | 0 | $0 |
| Corinne H Nevinny | Conselheiro | 24 de Maio de 2018 A | 43.283 | 0 | 0 | $0 |
| Thomas W Mitchell | Conselheiro | 28 de Maio de 2015 A | 1.000 | 0 | 0 | $0 |
| VALE WYLIE W | Conselheiro | 25 de Maio de 2011 A | 231.372 | 0 | 0 | $0 |
| Adrian Adams | Conselheiro | 30 de Junho de 2006 A | — | 0 | 0 | $0 |
| NEUROCRINE BIOSCIENCES INC | Detentor de 10% | 23 de Fevereiro de 2023 P | 8.575.316 | 0 | 0 | $0 |
| Jude Onyia | — | 4 de Agosto de 2026 G | 20.996 | 0 | 1 | $-1.762.710 |
| Shalini Sharp | — | 27 de Maio de 2026 A | 4.088 | 0 | 0 | $0 |
| MOLLICA JOSEPH A | — | 22 de Maio de 2017 A | 56.042 | 0 | 0 | $0 |
| HAWRAN PAUL W | — | 18 de Setembro de 2006 J | 132.000 | 0 | 0 | $0 |
| Lawrence Steinman | — | 2 de Março de 2005 S | 15.500 | 0 | 0 | $0 |
| CONLON PAUL J | — | 16 de Dezembro de 2003 S | 57.335 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 1 participação
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. ×3 declarações | 24 de Fevereiro de 2023 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 129 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,71% | 1.793 SH | 8 de Agosto de 2026 | Diário |
| PBE · Invesco Exchange-Traded Fund Trust | 2,51% | 55.704 SH | 8 de Agosto de 2026 | Diário |
| MCOW · Pacer Funds Trust | 2,17% | 162 NS | 30 de Abril de 2026 | N-PORT |
| FGSI · First Trust Exchange-Traded Fund IV | 2,01% | 457 NS | 30 de Abril de 2026 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Indexe… | 1,97% | 22.094 SH | 8 de Agosto de 2026 | Diário |
| SMRI · EA Series Trust | 1,95% | 79.947 NS | 30 de Abril de 2026 | N-PORT |
| GRPM · Invesco Exchange-Traded Fund Trust | 1,78% | 55.458 SH | 8 de Agosto de 2026 | Diário |
| XMHQ · Invesco Exchange-Traded Fund Trust | 1,74% | 599.955 SH | 8 de Agosto de 2026 | Diário |
| BUL · Pacer Funds Trust | 1,66% | 16.032 NS | 30 de Abril de 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,38% | 6.192 NS | 30 de Abril de 2026 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 1,29% | 23.318 NS | 31 de Maio de 2026 | N-PORT |
| IBB · iShares Trust | 1,22% | 725.434 SH | 8 de Agosto de 2026 | Diário |
| RFG · Invesco Exchange-Traded Fund Trust | 1,16% | 25.502 SH | 8 de Agosto de 2026 | Diário |
| AGNG · Global X Funds | 1,12% | 5.792 NS | 31 de Maio de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,12% | 5.472 SH | 8 de Agosto de 2026 | Diário |
| LABU · Direxion Shares ETF Trust | 0,95% | 37.476 NS | 30 de Abril de 2026 | N-PORT |
| AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… | 0,93% | 7.516 NS | 30 de Abril de 2026 | N-PORT |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,89% | 99.214 SH | 8 de Agosto de 2026 | Diário |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,87% | 57.454 NS | 30 de Abril de 2026 | N-PORT |
| IJK · iShares Trust | 0,86% | 588.275 SH | 8 de Agosto de 2026 | Diário |
| COWG · Pacer Funds Trust | 0,81% | 132.963 NS | 30 de Abril de 2026 | N-PORT |
| BIB · ProShares Trust | 0,80% | 3.712 NS | 31 de Maio de 2026 | N-PORT |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 0,79% | 57.321 SH | 8 de Agosto de 2026 | Diário |
| TMFX · RBB Fund, Inc. | 0,76% | 1.542 NS | 31 de Maio de 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 0,72% | 240 NS | 30 de Abril de 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,66% | 25.529 NS | 31 de Maio de 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,64% | 136 NS | 29 de Maio de 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,63% | 533 NS | 30 de Abril de 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,55% | 13.166 NS | 30 de Abril de 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,55% | 5.215 NS | 30 de Abril de 2026 | N-PORT |
| XJH · iShares Trust | 0,51% | 13.589 SH | 8 de Agosto de 2026 | Diário |
| ISCG · iShares Trust | 0,50% | 31.557 SH | 8 de Agosto de 2026 | Diário |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,49% | 13.131 SH | 8 de Agosto de 2026 | Diário |
| VBK · VANGUARD INDEX FUNDS | 0,46% | 1.331.820 SH | 8 de Agosto de 2026 | Diário |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,46% | 162.408 SH | 8 de Agosto de 2026 | Diário |
| QLV · FlexShares Trust | 0,46% | 5.915 NS | 30 de Abril de 2026 | N-PORT |
| IJH · iShares Trust | 0,44% | 3.469.295 SH | 8 de Agosto de 2026 | Diário |
| SDG · iShares Trust | 0,42% | 4.563 SH | 8 de Agosto de 2026 | Diário |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,40% | 15.614 NS | 30 de Abril de 2026 | N-PORT |
| IWP · iShares Trust | 0,39% | 493.090 SH | 8 de Agosto de 2026 | Diário |
| PTMC · Pacer Funds Trust | 0,39% | 11.519 NS | 30 de Abril de 2026 | N-PORT |
| USMV · iShares Trust | 0,35% | 534.448 SH | 8 de Agosto de 2026 | Diário |
| MVV · ProShares Trust | 0,34% | 3.468 NS | 31 de Maio de 2026 | N-PORT |
| SXQG · EXCHANGE TRADED CONCEPTS TRUST | 0,34% | 1.461 NS | 31 de Maio de 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,34% | 16.076 NS | 30 de Abril de 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,29% | 271.303 NS | 31 de Maio de 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,26% | 1.662 NS | 30 de Abril de 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,26% | 40.014 NS | 30 de Abril de 2026 | N-PORT |
| IYH · iShares Trust | 0,26% | 59.243 SH | 8 de Agosto de 2026 | Diário |
| ISCB · iShares Trust | 0,25% | 4.488 SH | 8 de Agosto de 2026 | Diário |